FLT1 and Stroke: Candesartan treated animals showed a visual increase in phospho-flt-1 (activation of VEGFR1) expression in the stroke hemisphere (Figure 6b) and increased phospho-flk-1(activation of VEGFR 2) expression in the nonstroke hemisphere (Figure 7b), but neither achieved statistical significance.